Transient p53 Reduction in Progenitor Cells for Diabetic Kidney Disease

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current endothelial lineage stem cell therapies for diabetic kidney disease are limited by the low quantity and quality of endogenous progenitor cells isolated from bone marrow and peripheral blood, and there is no definitive therapy for diabetic nephropathy.

Innovation Solution

Genetically modify endothelial progenitor cells to have transiently reduced p53 expression and increased manganese superoxide dismutase (MnSOD) expression, and transplant them under the kidney capsule to treat diabetic kidney disease.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If endogenous progenitor cells are isolated from bone marrow and peripheral blood, then stem cell therapy can be provided, but the quantity and quality of cells are insufficient

Engineering Contradiction:

Improvequantity of progenitor cellsVSAvoidquality of progenitor cells

Core Design Contradiction:

Quantity of substanceVSReliability

Solution Approach 1:

The patent applies parameter changes by transiently reducing p53 expression levels in endothelial progenitor cells. This parameter modification allows cells to survive and proliferate under conditions that would normally be lethal, thereby increasing both the quantity and quality of viable progenitor cells available for therapy without requiring large volumes of bone marrow or peripheral blood

Inventive Principle:

Principle #35Parameter changes

2Reliability

If p53 expression is reduced in endothelial progenitor cells, then cell survival and proliferation improve, but genomic stability may be compromised

Engineering Contradiction:

Improvecell survivalVSAvoidgenomic instability

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent employs dynamics by using transient p53 reduction rather than permanent knockout. The p53 suppression is temporary and reversible, allowing cells to survive and proliferate during the therapeutic window while eventually restoring normal p53 function to maintain genomic stability. This dynamic approach resolves the contradiction between needing low p53 for survival and needing high p53 for genomic integrity

Inventive Principle:

Principle #15Dynamics

Solution Approach 2:

The patent implements periodic action through transient p53 suppression followed by restoration. The p53 gene expression is temporarily reduced to enable cell expansion, then naturally or induced to return to normal levels. This periodic modulation allows the system to benefit from low p53 when needed while avoiding the long-term risks of permanent suppression, thereby maintaining both cell survival and genomic stability

Inventive Principle:

Principle #19Periodic action

Data Source

PatentUS20250320499A1METHOD OF TREATING A MAMMAL WITH DIABETES ASSOCIATED KIDNEY DISEASE USING LOCAL ADMINISTRATION OF STEM CELLS WITH TRANSIENTLY REDUCED p53

Publication Date: 2025.10.16 GEORGE WASHINGTON UNIVERSITY

AI summary

A composition comprising an endothelial progenitor cell genetically modified to have transiently reduced p53 expression for treating diabetic kidney disease and uses thereof.